Gérard Tobelem
Director/Board Member at OSE IMMUNOTHERAPEUTICS
Gérard Tobelem active positions
Companies | Position | Start | End |
---|---|---|---|
OSE IMMUNOTHERAPEUTICS | Director/Board Member | 2014-04-09 | - |
Independent Dir/Board Member | 2014-04-09 | - | |
Dendrogenix SA
Dendrogenix SA Pharmaceuticals: MajorHealth Technology Dendrogenix SA is a Belgian Belgium-based biotech company founded in 2018 that designs, develops, and brings proprietary molecules called dendrogenins to patients in the fields of hearing loss and neurology. The company is based in Liege, Belgium. Dendrogenins are cholesterol derivatives that stimulate cell differentiation in the immune and nervous system and induce growth of dendrites on dendritic cell and neuron precursors. The company has developed strong know-how in the chemical and biological aspects of dendrogenins. The company was founded by Stéphane Silvente, Gérard Tobelem, and Philippe Lefèbvre, with Stéphane Silvente serving as CEO since 2018. | Director/Board Member | 2017-12-31 | - |
Founder | 2017-12-31 | - |
Career history of Gérard Tobelem
Former positions of Gérard Tobelem
Companies | Position | Start | End |
---|---|---|---|
THERADIAG | Chairman | 2012-05-28 | 2018-10-30 |
Institut Sup Biotech De Paris | Director/Board Member | - | 2017-06-30 |
Établissement Français du Sang
Établissement Français du Sang BiotechnologyHealth Technology Établissement Français du Sang collects, prepares, qualifies and distributes blood transfusion products. The company is headquartered in Saint-Denis, France. | Chief Executive Officer | 2009-03-31 | - |
Chairman | 2009-03-31 | - | |
Lariboisière Hospital | Corporate Officer/Principal | - | - |
Université Paris Diderot-Paris 7 | Corporate Officer/Principal | - | - |
Louis Dreyfus Foundation | Director/Board Member | - | - |
Orphan Synergy Europe-Pharma SA
Orphan Synergy Europe-Pharma SA Pharmaceuticals: MajorHealth Technology Orphan Synergy Europe-Pharma SA engages in the development of immunotherapy products against late stage cancer. Its products include Tedopi as treatment for lung cancer and Memopi technology which helps the immune system to eliminate malignant cells. The company was founded by Dominique Costantini and Emile Loria on November 17, 2004 and is headquartered in Paris, France. | Director/Board Member | 2014-04-09 | - |
Independent Dir/Board Member | 2014-04-09 | - |
Statistics
International
France | 9 |
Belgium | 2 |
Operational
Director/Board Member | 5 |
Chairman | 2 |
Independent Dir/Board Member | 2 |
Sectoral
Health Technology | 6 |
Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
OSE IMMUNOTHERAPEUTICS | Health Technology |
Private companies | 7 |
---|---|
Theradiag SA
Theradiag SA Medical SpecialtiesHealth Technology Theradiag SA engages in the distribution, development, and manufacturing of in vitro diagnostic and theranostics tests. It operates through the following segments: Theranostics and Diagnostics. The Theranostics segment offers solutions for patients treated with anti-tumour necrosis factor alpha. The Diagnostics segment includes products for anti-immunity, genetics, allergy, infectious disease, drug of abuse, other diagnoses, and instrumentation. The company was founded on December 29, 1986 and is headquartered in Croissy-Beaubourg, France. | Health Technology |
Université Paris Diderot-Paris 7 | Consumer Services |
Établissement Français du Sang
Établissement Français du Sang BiotechnologyHealth Technology Établissement Français du Sang collects, prepares, qualifies and distributes blood transfusion products. The company is headquartered in Saint-Denis, France. | Health Technology |
Orphan Synergy Europe-Pharma SA
Orphan Synergy Europe-Pharma SA Pharmaceuticals: MajorHealth Technology Orphan Synergy Europe-Pharma SA engages in the development of immunotherapy products against late stage cancer. Its products include Tedopi as treatment for lung cancer and Memopi technology which helps the immune system to eliminate malignant cells. The company was founded by Dominique Costantini and Emile Loria on November 17, 2004 and is headquartered in Paris, France. | Health Technology |
Louis Dreyfus Foundation | |
Lariboisière Hospital | |
Dendrogenix SA
Dendrogenix SA Pharmaceuticals: MajorHealth Technology Dendrogenix SA is a Belgian Belgium-based biotech company founded in 2018 that designs, develops, and brings proprietary molecules called dendrogenins to patients in the fields of hearing loss and neurology. The company is based in Liege, Belgium. Dendrogenins are cholesterol derivatives that stimulate cell differentiation in the immune and nervous system and induce growth of dendrites on dendritic cell and neuron precursors. The company has developed strong know-how in the chemical and biological aspects of dendrogenins. The company was founded by Stéphane Silvente, Gérard Tobelem, and Philippe Lefèbvre, with Stéphane Silvente serving as CEO since 2018. | Health Technology |
- Stock Market
- Insiders
- Gérard Tobelem
- Experience